Skip to main content

Reducing the cost, time, and ethical burden of preclinical research in the pharmaceutical industry


Recent advances in genomics, molecular science, and big data are changing the way we define and target diseases, but drug discovery is still a time-consuming, expensive and risky process. Genome Biologics provides a unique combination of tools – GENIMAPS and GENISYST – to provide an integrated platform, with a disruptive effect on the time, cost and risk of drug discovery and pre-clinical trial development.
GENISYST uses a unique transgenic methodology to allow up to 50 genes to be expressed in one animal, directly in target tissue, without affecting the genome. This methodology removes the need for breeding, radically reducing the number of animals needed to make a transgenic animal model by a factor of 100, and enables transgenic large animal models, a current commercial gap in the market. The toolkit reduces the time to prepare animal models, and the cost of drug discovery and pre-clinical trials, by an order of magnitude. The impact of this is cheaper, more rapidly developed, drugs, with a greater target to market success rate.
GENIMAPS combines big data, AI and a unique multi-omics approach to make rapid and precise matches between disease indicators and compound behaviours, allow rapid identification of targets, genetic expression, and compound matches. As well as precision medicine, GENIMAPS also allows the rapid evaluation of an existing pipeline, allowing repositioning of a company’s existing, FDA approved assets (or orphan drugs) – increasing the return on public and private investment.

Zaproszenie do składania wniosków


Zobacz inne projekty w ramach tego zaproszenia

Szczegółowe działanie



Wkład UE netto
€ 2 425 325,00
Danziger Weg 17
61476 Kronberg Im Taunus

Zobacz na mapie

Darmstadt Hochtaunuskreis
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Finansowanie spoza UE
€ 1 039 425,00